Jesús Rodríguez‐Baño
A5063919113- Antibiotic Resistance in Bacteria
- Antibiotic Use and Resistance
- Bacterial Identification and Susceptibility Testing
- Antibiotics Pharmacokinetics and Efficacy
- Antimicrobial Resistance in Staphylococcus
- Urinary Tract Infections Management
- Nosocomial Infections in ICU
- Pneumonia and Respiratory Infections
- Infective Endocarditis Diagnosis and Management
- COVID-19 Clinical Research Studies
- Vibrio bacteria research studies
- Escherichia coli research studies
- Streptococcal Infections and Treatments
- Pharmaceutical and Antibiotic Environmental Impacts
- Enterobacteriaceae and Cronobacter Research
- Bacterial biofilms and quorum sensing
- Long-Term Effects of COVID-19
- Sepsis Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Antifungal resistance and susceptibility
- Patient Satisfaction in Healthcare
- Central Venous Catheters and Hemodialysis
- Clostridium difficile and Clostridium perfringens research
- Influenza Virus Research Studies
- Respiratory viral infections research
Hospital Universitario Virgen Macarena
2016-2025
Universidad de Sevilla
2016-2025
Centro de Investigación Biomédica en Red
2021-2025
Instituto de Biomedicina de Sevilla
2016-2025
Instituto de Salud Carlos III
2016-2025
Consejo Superior de Investigaciones Científicas
2017-2025
Integral University
2024
Centre for Biomedical Network Research on Rare Diseases
2022-2024
Instituto de Investigación Biomédica de Málaga
2024
Hospital Regional Universitario de Málaga
2024
Escherichia coli sequence type 131 (ST131) is a globally disseminated, multidrug resistant (MDR) clone responsible for high proportion of urinary tract and bloodstream infections. The rapid emergence successful spread E. ST131 strongly associated with several factors, including resistance to fluoroquinolones, virulence gene content, the possession 1 fimbriae FimH30 allele, production CTX-M-15 extended spectrum β-lactamase (ESBL). Here, we used genome sequencing examine molecular epidemiology...
ABSTRACT Infections due to extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (ESBLEC) in nonhospitalized patients seem be emerging different countries. Their incidence, epidemiology, and clinical impact the community have not been studied. We describe epidemiology features of infections caused by ESBLEC Spain results a case-control study performed investigate risk factors associated with acquisition these organisms. The clonal relatedness organisms was assessed repetitive...
Infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are increasing in frequency and associated with high mortality rates. Circulation of CTX-M-type ESBLs the community is particular concern, because it may confound standard infection-control measures.We analyzed results epidemiologic studies infection ESBL-producing nonhospitalized patients from 6 centers Europe, Asia, North America. Risk factors for an organism were identified univariate multivariate...
<h3>Background</h3> Extended-spectrum β-lactamase (ESBL)-producing<i>Escherichia coli</i>is an increasingly important group of community pathogens worldwide. These organisms are frequently resistant to many the antimicrobial agents usually recommended for treatment infections caused by<i>E coli</i>, such as penicillins, cephalosporins, fluoroquinolones, and trimethoprim-sulfamethoxazole. Data concerning risk factors, clinical features, therapeutic options scarce. <h3>Methods</h3> A...
Background. Extended-spectrum ß-lactamase–producing Escherichia coli (ESBL-EC) is an important cause of invasive infections. Alternatives to carbapenems—considered the drugs choice—are needed because emergence carbapenemase-producing enterobacteria. The efficacy ß-lactam/ß-lactam inhibitors (BLBLI) in such infections controversial.
BackgroundThere is little clinical information about community-onset bloodstream infections (COBSIs) caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBLEC). We investigated the prevalence and risk factors for COBSI due to ESBLEC, described their features impact of ESBLEC on 14-day mortality.
Infections with carbapenem-resistant Enterobacteriaceae (CRE) are increasingly being reported from patients in healthcare settings. They associated high patient morbidity, attributable mortality and hospital costs. Patients who "at-risk" may be carriers of these multidrug-resistant (MDR-E). The purpose this guidance is to raise awareness identify the when admitted a setting outline effective infection prevention control measures halt entry spread CRE. was created by group experts were...
The bacille Calmette-Guérin (BCG) vaccine has immunomodulatory "off-target" effects that have been hypothesized to protect against coronavirus disease 2019 (Covid-19).
Lack of specific definitions clinical characteristics, disease severity, and risk preventive factors post-COVID-19 syndrome (PCS) severely impacts research discovery new therapeutics drugs.This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- in-patients followed at 3-, 6-, 12-month diagnosis, with assessment biochemical features, antibody (Ab) response, Variant Concern (VoC), physical mental quality life (QoL)....